HS-10502
- Generic Name
- HS-10502
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Prostatic CancerOvarian CancerBreast CancerColorectal CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 318
- Registration Number
- NCT05740956
- Locations
- 🇨🇳
Cancer Hospital Chinese Acedemy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath